These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 30065653)

  • 1. Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization.
    Hua S; de Matos MBC; Metselaar JM; Storm G
    Front Pharmacol; 2018; 9():790. PubMed ID: 30065653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and Therapeutic Nanomedicine.
    Joo J
    Adv Exp Med Biol; 2021; 1310():401-447. PubMed ID: 33834444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems for Cancer Treatment.
    Nayak R; Meerovich I; Dash AK
    AAPS PharmSciTech; 2019 Apr; 20(4):160. PubMed ID: 30968269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved extraction efficiency of natural nanomaterials in soils to facilitate their characterization using a multimethod approach.
    Loosli F; Yi Z; Wang J; Baalousha M
    Sci Total Environ; 2019 Aug; 677():34-46. PubMed ID: 31051381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.
    Zhang P; Xiao Y; Sun X; Lin X; Koo S; Yaremenko AV; Qin D; Kong N; Farokhzad OC; Tao W
    Med; 2023 Mar; 4(3):147-167. PubMed ID: 36549297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current hurdles to the translation of nanomedicines from bench to the clinic.
    Đorđević S; Gonzalez MM; Conejos-Sánchez I; Carreira B; Pozzi S; Acúrcio RC; Satchi-Fainaro R; Florindo HF; Vicent MJ
    Drug Deliv Transl Res; 2022 Mar; 12(3):500-525. PubMed ID: 34302274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation.
    Mills JA; Liu F; Jarrett TR; Fletcher NL; Thurecht KJ
    Biomater Sci; 2022 Jun; 10(12):3029-3053. PubMed ID: 35419582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
    Pearce AK; O'Reilly RK
    Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticulate-based drug delivery systems for small molecule anti-diabetic drugs: An emerging paradigm for effective therapy.
    Uppal S; Italiya KS; Chitkara D; Mittal A
    Acta Biomater; 2018 Nov; 81():20-42. PubMed ID: 30268916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicine drug development: a scientific symposium entitled "Charting a roadmap to commercialization".
    Finch G; Havel H; Analoui M; Barton RW; Diwan AR; Hennessy M; Reddy V; Sadrieh N; Tamarkin L; Wolfgang M; Yerxa B; Zolnik B; Liu M
    AAPS J; 2014 Jul; 16(4):698-704. PubMed ID: 24821054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microfluidic Manufacture of Lipid-Based Nanomedicines.
    Osouli-Bostanabad K; Puliga S; Serrano DR; Bucchi A; Halbert G; Lalatsa A
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanosize drug delivery system.
    Mukherjee B
    Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are existing standard methods suitable for the evaluation of nanomedicines: some case studies.
    Gioria S; Caputo F; Urbán P; Maguire CM; Bremer-Hoffmann S; Prina-Mello A; Calzolai L; Mehn D
    Nanomedicine (Lond); 2018 Mar; 13(5):539-554. PubMed ID: 29381129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
    Halwani AA
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational formulation of nanoparticle therapeutics from laboratory discovery to clinical scale.
    Feng J; Markwalter CE; Tian C; Armstrong M; Prud'homme RK
    J Transl Med; 2019 Jun; 17(1):200. PubMed ID: 31200738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.